Electronic cigarettes pose less danger than traditional smoking

Jul.08.2022
Electronic cigarettes pose less danger than traditional smoking
Evidence shows that vaping is less harmful than smoking and can help smokers quit, but media coverage has hindered public understanding.

The evidence is clear: vaping is less dangerous than smoking and can help many people quit their deadly smoking habit. No public data can refute these two conclusions, but tobacco control researchers, activists, and federal regulatory agencies often deny or downplay these observations. This contaminates the public's understanding of electronic cigarettes and prevents smokers from trying out alternative solutions that could potentially save their lives.


Using electronic cigarettes helped me successfully quit smoking, according to a recent conclusion published in the American Journal of Preventive Medicine. Medscape reported on June 20 that "an increasing number of American adults believe that electronic cigarettes are more harmful than traditional cigarettes.


Why are the public afraid of electronic cigarettes?


The author analyzed data collected as part of the Health Information National Trends Survey (HINTS), which is a nationally representative survey conducted through mail that asks American adults about their attitudes towards cancer and other health-related information. The data was collected over five cycles between January 2018 and May 2020, with over 3000 respondents included in the final analysis each year (3360 in 2018, 3217 in 2019, and 3677 in 2020). The author reports that...


The relative perceived harm of electronic cigarettes versus traditional cigarettes was assessed through the following question with six possible answers: Compared to smoking, would you say that electronic cigarettes are... Respondents were categorized as perceiving electronic cigarettes to be less harmful (less harmful or much less harmful) than traditional cigarettes, equally harmful, or more harmful (more harmful or much more harmful) than traditional cigarettes.


The author suggests that the negative shift in perception may have been driven by the media's coverage of the so-called "EVALI outbreak". From 2019 to 2020, over 2,000 individuals were hospitalized due to e-cigarette related lung injuries and 68 people died.


These cases were not caused by electronic cigarettes themselves, which were mistakenly maintained by the Centers for Disease Control and Prevention for a few months, but by devices purchased illegally for vaping THC or CBD. These chemicals, derived from cannabis rather than tobacco, were mixed with vitamin E acetate which may have contributed to the reported lung injuries. Dr. Josh Bloom provided a helpful explanation of the chemical reaction behind this phenomenon in the story, which subsequent research has confirmed.


During the outbreak of EVALI, journalists did what they often do without having all the facts: they amplified the risk, with the tacit approval of the Centers for Disease Control, but were not interested in reporting on the controversy surrounding the decision. According to the study authors:


In March and April of 2020, there was a high level of harmful relative opinions. This suggests that misunderstandings have persisted since the initial discovery of the connection to vitamin E acetate in September 2019, possibly due to media coverage not remaining at the same level after the source of the epidemic was determined.


The trend is still continuing.


EVALI is no longer a major public health concern, but controversial ideological radicalism and careless reporting continue to undermine electronic cigarettes as a harm reduction tool in today's society. Researchers have published low-quality studies alleging serious health consequences from using e-cigarettes, and the media dutifully reported on these findings. The ACSH and other scientifically-minded media outlets have corrected the propaganda, but unfortunately, this good news has not garnered as much attention as sensational and scary headlines.


Experts recognize the issue and acknowledge the need for a solution. According to a doctor, we are effective at communicating the harmful effects of smoking and the dangers of tobacco in public health. Ashley Brooks-Russell, associate professor at the Colorado School of Public Health, stated to Medscape Medical News that we struggle to discuss smaller choices, such as the lesser harm of e-cigarettes compared to smoking.


Dr. Russell is correct, but I will go even further. Even though researchers have documented the harm caused by common anti-vaping metaphors, tobacco researchers cannot abandon their skepticism of e-cigarettes. As the authors of the study themselves have written,


Electronic cigarettes contain high levels of nicotine and appealing flavors that may lead to addiction and the use of combustible tobacco products among adolescents and young adults.


The sentence is at least partially false. Many electronic cigarettes contain little to no nicotine. Flavored electronic cigarettes do not encourage youth to use any tobacco products, and there is no concrete evidence to support this speculation. The author also reiterated the anti-electronic cigarette stance, which has become a staunch article among tobacco researchers: "The risks associated with long-term use are still unclear." This is undoubtedly true, as no one has a crystal ball, but public health researchers often use such language to suggest that we will discover some serious risks associated with electronic cigarettes in the future.


The American Cancer Society claims that the long-term risks of only using electronic cigarettes are not yet fully clear. However, there is increasing evidence that using e-cigarettes has negative effects on the cardiovascular system and lungs. If immediate action is not taken to stop the widespread use of these products, the long-term adverse health effects will increase.


Can you imagine a large medical institution issuing a statement similar to this regarding the use of COVID-19 vaccines or puberty blockers for treating gender dysphoria? After all, we do not know the potential long-term effects of these powerful drugs on those who take them. Of course, until we have a better understanding of these products, we must halt their "popular use," shouldn't we?


If these issues are frustrating you, then maybe you're starting to understand why the popular rhetoric surrounding e-cigarettes is so absurd. Properly evaluating any product requires accurately balancing its risks and benefits. No one is claiming that e-cigarettes are risk-free; they are an effective intervention aimed at reducing the harm of smoking, which is killing people all over the world.


Given this standard, speculating about potential hazards we may discover one day is a foolish thought exercise. Let the public know what we know today: for adult smokers who want to quit smoking, electronic cigarettes are a low-risk option.


This article is compiled from third-party information and is only intended for educational purposes. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01